Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965534 | 0.91 | ESR1 (0.37) | ESR1ESR2HDAC6ACKR3HDAC8 | |
| SCHEMBL3965551 | 0.84 | ESR1 (0.36) | ESR1ESR2ACKR3DRD2NOTUM | |
| SCHEMBL507887 | 0.81 | ESR1 (0.43) | ESR1ESR2HDAC6ACKR3NOTUM | |
| SCHEMBL3965505 | 0.78 | HTR2A (0.43) | DRD4DRD2PTGES | |
| SCHEMBL2368626 | 0.78 | ESR1 (0.38) | ESR1ESR2ACKR3PKMABHD6 | |
| SCHEMBL2584808 | 0.77 | ESR1 (0.39) | ESR1ESR2HDAC6ACKR3PTGES | |
| SCHEMBL2255041 | 0.77 | ESR1 (0.48) | ESR1ESR2ACKR3ARNOTUM | |
| SCHEMBL3963048 | 0.76 | ESR1 (0.43) | ESR1ESR2ACKR3PKMABHD6 | |
| SCHEMBL3964266 | 0.76 | NAMPT (0.38) | ESR1ESR2DRD2 | |
| SCHEMBL2584415 | 0.74 | ESR1 (0.37) | ESR1ESR2HDAC6ACKR3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1926712-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | ESR1 175/4885ESR2 150/4885HDAC6 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.